These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 24372395)

  • 1. Reversible phospho-Smad3 signalling between tumour suppression and fibrocarcinogenesis in chronic hepatitis B infection.
    Deng YR; Yoshida K; Jin QL; Murata M; Yamaguchi T; Tsuneyama K; Moritoki Y; Niu JQ; Matsuzaki K; Lian ZX
    Clin Exp Immunol; 2014 Apr; 176(1):102-11. PubMed ID: 24372395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B virus X protein shifts human hepatic transforming growth factor (TGF)-beta signaling from tumor suppression to oncogenesis in early chronic hepatitis B.
    Murata M; Matsuzaki K; Yoshida K; Sekimoto G; Tahashi Y; Mori S; Uemura Y; Sakaida N; Fujisawa J; Seki T; Kobayashi K; Yokote K; Koike K; Okazaki K
    Hepatology; 2009 Apr; 49(4):1203-17. PubMed ID: 19263472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma.
    Matsuzaki K; Murata M; Yoshida K; Sekimoto G; Uemura Y; Sakaida N; Kaibori M; Kamiyama Y; Nishizawa M; Fujisawa J; Okazaki K; Seki T
    Hepatology; 2007 Jul; 46(1):48-57. PubMed ID: 17596875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Linker phosphorylation of Smad3 promotes fibro-carcinogenesis in chronic viral hepatitis of hepatocellular carcinoma.
    Murata M; Yoshida K; Yamaguchi T; Matsuzaki K
    World J Gastroenterol; 2014 Nov; 20(41):15018-27. PubMed ID: 25386050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Smad3 phospho-isoform signaling in hepatitis C virus-related chronic liver diseases.
    Yamaguchi T; Yoshida K; Murata M; Matsuzaki K
    World J Gastroenterol; 2014 Sep; 20(35):12381-90. PubMed ID: 25253939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of telbivudine therapy in liver failure patients with chronic hepatitis B virus infection.
    Wang L; Chen H; Fan C; Gong Z
    J Med Virol; 2013 Nov; 85(11):1907-12. PubMed ID: 23852947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of c-Jun NH2-terminal kinase switches Smad3 signaling from oncogenesis to tumor- suppression in rat hepatocellular carcinoma.
    Nagata H; Hatano E; Tada M; Murata M; Kitamura K; Asechi H; Narita M; Yanagida A; Tamaki N; Yagi S; Ikai I; Matsuzaki K; Uemoto S
    Hepatology; 2009 Jun; 49(6):1944-53. PubMed ID: 19418558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telbivudine versus lamivudine and entecavir for treatment-naïve decompensated hepatitis B virus-related cirrhosis.
    Yue-Meng W; Li YH; Wu HM; Yang J; Xu Y; Yang LH; Yang JH
    Clin Exp Med; 2017 May; 17(2):233-241. PubMed ID: 27094312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Forty-eight-week retrospective study of telbivudine and lamivudine treatment in patients with hepatitis B-related cirrhosis.
    Han Z; Shi Y; Zhu J; Chen Y; Yin F; Xia L; Luo G; Gao Z; Liu J; Jia G; Li C; Zhou X; Han Y
    J Viral Hepat; 2013 Apr; 20 Suppl 1():58-64. PubMed ID: 23458526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucin1 shifts Smad3 signaling from the tumor-suppressive pSmad3C/p21(WAF1) pathway to the oncogenic pSmad3L/c-Myc pathway by activating JNK in human hepatocellular carcinoma cells.
    Li Q; Liu G; Yuan H; Wang J; Guo Y; Chen T; Zhai R; Shao D; Ni W; Tai G
    Oncotarget; 2015 Feb; 6(6):4253-65. PubMed ID: 25714018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Smad Phospho-Isoforms for Hepatocellular Carcinoma Risk Assessment in Patients with Nonalcoholic Steatohepatitis.
    Suwa K; Yamaguchi T; Yoshida K; Murata M; Ichimura M; Tsuneyama K; Seki T; Okazaki K
    Cancers (Basel); 2020 Jan; 12(2):. PubMed ID: 31991602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Telbivudine treatment on cirrhosis resulting from chronic hepatitis B].
    Liang J; Han T; Xiao SX
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jan; 17(1):24-7. PubMed ID: 19203447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance of ground glass hepatocytes to oral antivirals in chronic hepatitis B patients and implication for the development of hepatocellular carcinoma.
    Tsai HW; Lin YJ; Wu HC; Chang TT; Wu IC; Cheng PN; Yen CJ; Chan SH; Huang W; Su IJ
    Oncotarget; 2016 May; 7(19):27724-34. PubMed ID: 27027237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphorylated Smad2 and Smad3 signaling: Shifting between tumor suppression and fibro-carcinogenesis in chronic hepatitis C.
    Yamaguchi T; Matsuzaki K; Inokuchi R; Kawamura R; Yoshida K; Murata M; Fujisawa J; Fukushima N; Sata M; Kage M; Nakashima O; Tamori A; Kawada N; Tsuneyama K; Dooley S; Seki T; Okazaki K
    Hepatol Res; 2013 Dec; 43(12):1327-42. PubMed ID: 23458062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. c-Jun N-terminal kinase inhibitor favors transforming growth factor-β to antagonize hepatitis B virus X protein-induced cell growth promotion in hepatocellular carcinoma.
    Wu YH; Ai X; Liu FY; Liang HF; Zhang BX; Chen XP
    Mol Med Rep; 2016 Feb; 13(2):1345-52. PubMed ID: 26648552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of telbivudine versus lamivudine in interrupting perinatal transmission of hepatitis B virus.
    Yu MM; Jiang Q; Ji Y; Wu KH; Ju LL; Tang X; Yang YF
    J Clin Virol; 2014 Sep; 61(1):55-60. PubMed ID: 24994007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Smad3 Phospho-Isoform Signaling in Nonalcoholic Steatohepatitis.
    Yamaguchi T; Yoshida K; Murata M; Suwa K; Tsuneyama K; Matsuzaki K; Naganuma M
    Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35682957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histological outcome for chronic hepatitis B patients treated with entecavir vs lamivudine-based therapy.
    Wang JL; Du XF; Chen SL; Yu YQ; Wang J; Hu XQ; Shao LY; Chen JZ; Weng XH; Zhang WH
    World J Gastroenterol; 2015 Aug; 21(32):9598-606. PubMed ID: 26327767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of hepatocellular carcinoma in hepatitis B virus infection.
    Lim SG; Mohammed R; Yuen MF; Kao JH
    J Gastroenterol Hepatol; 2009 Aug; 24(8):1352-7. PubMed ID: 19702903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir.
    Park H; Park JY; Kim SU; Kim DY; Han KH; Chon CY; Ahn SH
    World J Gastroenterol; 2013; 19(43):7671-9. PubMed ID: 24431895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.